Summary of Study ST001136
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000760. The data can be accessed directly via it's Project DOI: 10.21228/M8FH6C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001136 |
| Study Title | Metabolme analysis of OPC-163493 on the Liver of ZDF rats (part-II) |
| Study Type | Long-term in vivo test |
| Study Summary | Metabolome analysis were on the 24 samples of ZDF rats that were treated with OPC-163493 for 6-weeks. The 24 samples were composed of 3 different groups (Vehicles, OPC-163493 treatment, and baseline control; each n=8). |
| Institute | Otsuka Pharmaceutical Co., Ltd. |
| Last Name | Kanemoto |
| First Name | Naohide |
| Address | 463-10 Kagasuno Kawauchi-cho Tokushima 771-0192, Japan |
| Kanemoto.Naohide@otsuka.jp | |
| Phone | 81-03-6717-1400 |
| Submit Date | 2019-02-07 |
| Analysis Type Detail | LC-MS |
| Release Date | 2019-03-06 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000760 |
| Project DOI: | doi: 10.21228/M8FH6C |
| Project Title: | Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler |
| Project Summary: | Inducing mitochondrial uncoupling (mUncoupling) is an attractive therapeutic strategy for treating metabolic diseases because it leads to calorie-wasting by reducing the efficiency of oxidative phosphorylation (OXPHOS) in mitochondria. Here we report a safe mUncoupler, OPC-163493, which has unique pharmacokinetic characteristics. OPC-163493 shows a good bioavailability upon oral administration and primarily distributed to specific organs: the liver and kidneys, avoiding systemic toxicities. It exhibitsinsulin-independent antidiabetic effects in multiple animal models of type I and type II diabetes and antisteatotic effects in fatty liver models. These beneficial effects can be explained by the improvement of glucose metabolism and enhancement of energy expenditure by OPC-163493 in the liver. Moreover, OPC-163493 treatment lowered blood pressure, extended survival, and improved renal function in the rat model of stroke/hypertension, possibly by enhancing NO bioavailability in blood vessels and reducing mitochondrial ROS production. OPC-163493 is a liver-localized/targeted mUncoupler that ameliorates various complications of diabetes. |
| Institute: | Otsuka Pharmaceutical Co., Ltd. |
| Last Name: | Kanemoto |
| First Name: | Naohide |
| Address: | 463-10 Kagasuno Kawauchi-cho, Tokushima, Tokusima, 770-0865, Japan |
| Email: | Kanemoto.Naohide@otsuka.jp |
| Phone: | +81-88-665-2126 |
Subject:
| Subject ID: | SU001197 |
| Subject Type: | Mammal |
| Subject Species: | Rattus norvegicus |
| Taxonomy ID: | 10116 |
| Genotype Strain: | ZDF rats |
| Gender: | Not applicable |
Factors:
Subject type: Mammal; Subject species: Rattus norvegicus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Genotype | Treatment | Duration (weeks) |
|---|---|---|---|---|
| SA078237 | Baseline control-106 | 11-week-old ZDF rat | - | - |
| SA078238 | Baseline control-107 | 11-week-old ZDF rat | - | - |
| SA078239 | Baseline control-105 | 11-week-old ZDF rat | - | - |
| SA078240 | Baseline control-104 | 11-week-old ZDF rat | - | - |
| SA078241 | Baseline control-101 | 11-week-old ZDF rat | - | - |
| SA078242 | Baseline control-103 | 11-week-old ZDF rat | - | - |
| SA078243 | Baseline control-108 | 11-week-old ZDF rat | - | - |
| SA078244 | Baseline control-102 | 11-week-old ZDF rat | - | - |
| SA078253 | OPC-13 | 17-week-old ZDF rat | 6 | 6 |
| SA078254 | OPC-10 | 17-week-old ZDF rat | 6 | 6 |
| SA078255 | OPC-9 | 17-week-old ZDF rat | 6 | 6 |
| SA078256 | OPC-11 | 17-week-old ZDF rat | 6 | 6 |
| SA078257 | OPC-12 | 17-week-old ZDF rat | 6 | 6 |
| SA078258 | OPC-15 | 17-week-old ZDF rat | 6 | 6 |
| SA078259 | OPC-14 | 17-week-old ZDF rat | 6 | 6 |
| SA078260 | OPC-16 | 17-week-old ZDF rat | 6 | 6 |
| SA078245 | Vehicle-5 | 17-week-old ZDF rat | - | 6 |
| SA078246 | Vehicle-4 | 17-week-old ZDF rat | - | 6 |
| SA078247 | Vehicle-3 | 17-week-old ZDF rat | - | 6 |
| SA078248 | Vehicle-6 | 17-week-old ZDF rat | - | 6 |
| SA078249 | Vehicle-1 | 17-week-old ZDF rat | - | 6 |
| SA078250 | Vehicle-8 | 17-week-old ZDF rat | - | 6 |
| SA078251 | Vehicle-7 | 17-week-old ZDF rat | - | 6 |
| SA078252 | Vehicle-2 | 17-week-old ZDF rat | - | 6 |
| Showing results 1 to 24 of 24 |
Collection:
| Collection ID: | CO001191 |
| Collection Summary: | After euthanasia by exsanguination under isoflurane anesthesia, a piece of liver was taken from the left lateral lobe on the treated rats, weighed at approximately 50mg, and immediately frozen in liquid nitrogen. |
| Sample Type: | Liver |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR001212 |
| Treatment Summary: | The baseline control, the liver samples of ZDF rats were taken from the baseline control group of 11-week-old ZDF rats. And at the same time, the other 2 comparing groups were started on oral administration of OPC-163493 or vehicle solution for 6-weeks. After 6-week dosing, liver samples were taken from both groups, and the liver metabolites of all three groups including the baseline controls were analyzed. |
| Treatment Dose: | 0mg/kg/day, 6mg/kg/day |
Sample Preparation:
| Sampleprep ID: | SP001205 |
| Sampleprep Summary: | The frozen liver samples were plunged into 50% acetonitrile/Milli-Q water containing internal standard. The sample was homogenized and then centrifuged. Subsequently, 800 uL of upper aqueous layer was filtered through a 5-kDa cutoff filter. The filtrate was centrifugally concentrated and re-suspended in 50 uL of Milli-Q water. |
| Processing Storage Conditions: | 4℃ |
| Extract Storage: | -80℃ |
| Sample Resuspension: | 50 uL Mili-Q |
Combined analysis:
| Analysis ID | AN001862 | AN001863 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | CE | CE |
| Chromatography system | Agilent 7100 CE | Agilent 7100 CE |
| Column | Fused silica capillary, i.d. 50 μm × 80 cm | Fused silica capillary, i.d. 50 μm × 80 cm |
| MS Type | ESI | ESI |
| MS instrument type | Other | Triple quadrupole |
| MS instrument name | Agilent 6210 TOF | Agilent 6460 QQQ |
| Ion Mode | UNSPECIFIED | UNSPECIFIED |
| Units | Concentration (nmol/g tissue) | Concentration (nmol/g tissue) |
Chromatography:
| Chromatography ID: | CH001348 |
| Chromatography Summary: | capillary electrophoresis was connected with time-of-flight mass spectrometry (CE-TOFMS) for cation analysis and tandem mass spectrometry (CE-MS/MS) for anion. |
| Instrument Name: | Agilent 7100 CE |
| Column Name: | Fused silica capillary, i.d. 50 μm × 80 cm |
| Chromatography Type: | CE |
MS:
| MS ID: | MS001722 |
| Analysis ID: | AN001862 |
| Instrument Name: | Agilent 6210 TOF |
| Instrument Type: | Other |
| MS Type: | ESI |
| MS Comments: | The spectrometer was scanned from m/z 50 to 1,000. Peaks were extracted using automatic integration software MasterHands (Keio University, Tsuruoka, Japan) in order to obtain peak information including m/z, migration time for CE-TOFMS measurement (MT) and peak area. Signal peaks corresponding to isotopomers, adduct ions, and other product ions of known metabolites were excluded, and remaining peaks were annotated with putative metabolites from the HMT metabolite database based on their MTs and m/z values determined by TOFMS. The tolerance range for the peak annotation was configured at ±0.5 min for MT and ±10 ppm for m/z. In addition, peak areas were normalized against those of the internal standards and then the resultant relative area values were further normalized by sample amount. |
| Ion Mode: | UNSPECIFIED |
| MS ID: | MS001723 |
| Analysis ID: | AN001863 |
| Instrument Name: | Agilent 6460 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | The spectrometer was scanned from m/z 50 to 1,000. Peaks were extracted using MasterHands, automatic integration software (Keio University, Tsuruoka, Yamagata, Japan) and MassHunter Quantitative Analysis B.04.00 (Agilent Technologies) in order to obtain peak information including m/z, peak area, and migration time (MT). Signal peaks were annotated according to the HMT metabolite database based on their m/z values with the MTs. The peak area of each metabolite was normalized with respect to the area of the internal standard and metabolite concentration was evaluated by standard curves with three-point calibrations using each standard compound. |
| Ion Mode: | UNSPECIFIED |
